Clinical trials of natural products as chemopreventive agents for prostate cancer

Bibliography

• AKAZA H, USAMI M, HINOTSU S et al.: Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J. Clin. Oncol. (2004) 34(6):329-336.
   Google Scholar
• LANDIS SH, MURRAY T, BOLDEN S, WINGO PA: Cancer statistics. CA Cancer J. Clin. (1998) 48(1):6-29.
   Google Scholar
• MORTON MS, GRIFFITHS K, BLACKLOCK N: The preventive role of diet in prostatic disease. Br. J. Urol. (1996) 77(4):481-493.
   Web of Science ®Google Scholar
• GIOVANNUCCI E, RIMM EB, LIU Y, STAMPFER MJ, WILLETT WC: A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl. Cancer Inst. (2002) 94(5):391-398.
   Google Scholar
• TRICHOPOULOU A, LAGIOU P, KUPER H, TRICHOPOULOS D: Cancer and Mediterranean dietary traditions. Cancer Epidemiol. Biomarkers Prev. (2000) 9(9):869-873.
   Web of Science ®Google Scholar
• SPORN MB, SUH N: Chemoprevention: an essential approach to controlling cancer. Nat. Rev. Cancer (2002) 2(7):537-543.
   PubMed Web of Science ®Google Scholar
• KLEIN EA, THOMPSON IM: Update on chemoprevention of prostate cancer. Curr. Opin. Urol. (2004) 14(3):143-149.
   Web of Science ®Google Scholar
• JIAN L, XIE LP, LEE AH, BINNS CW: Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int. J. Cancer (2004) 108(1):130-135.
   PubMed Web of Science ®Google Scholar
• HASTAK K, GUPTA S, AHMAD N, AGARWAL MK, AGARWAL ML, MUKHTAR H: Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene (2003) 22(31):4851-4589.
   PubMed Web of Science ®Google Scholar
• CHUNG LY, CHEUNG TC, KONG SK, FUNG KP, CHOY YM, CHAN ZY: Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. Life Sci. (2001) 68(10):1207-1214.
   Google Scholar
• PASCHKA AG, BUTLER R, YOUNG CY: Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett. (1998) 130(1-2):1-7.
   Web of Science ®Google Scholar
• GUPTA S, AHMAD N, NIEMINEN AL, MUKHTAR H: Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol. Appl. Pharmacol. (2000) 164(1):82-90.
   Google Scholar
• LIAO S, HIIPAKKA RA: Selective inhibition of steroid 5α-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun. (1995) 214:833–838.
   Google Scholar
• HIIPAKKA RA, ZHANG HZ, DAI W, DAI Q, LIAO S: Structure-activity relationships for inhibition of human 5α-reductases by polyphenols. Biochem. Pharmacol. (2002) 63(6):1165-1176.
   Google Scholar
• REN F, ZHANG S, MITCHELL SH, BUTLER R, YOUNG CY: Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene (2000) 19(15):1924-1932.
   PubMed Web of Science ®Google Scholar
• CAPORALI A, DAVALLI P, ASTANCOLLE S, D’ARCA D, BRAUSI M, BETTUZZI S: The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis (2004) 25(11):2217-2224.
   PubMed Web of Science ®Google Scholar
• GUPTA S, HASTAK K, AHMAD N, LEWIN JS, MUKHTAR H: Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl. Acad. Sci. USA (2001) 98(18):10350-10355.
   Google Scholar
• SHIMIZU M, DEGUCHI A, LIM JT, MORIWAKI H, KOPELOVICH L, WEINSTEIN IB: (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin. Cancer Res. (2005) 11(7):2735-2746.
   Google Scholar
• BETTUZZI S, BRAUSI M, RIZZI F, CASTAGNETTI G, PERACCHIA G, CORTI A: Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. (2006) 66(2):1234-1240.
   PubMed Web of Science ®Google Scholar
• JATOI A, ELLISON N, BURCH PA et al.: A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer (2003) 97(6):1442-1446.
   PubMed Web of Science ®Google Scholar
• CHOAN E, SEGAL R, JONKER D et al.: A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol. Oncol. (2005) 23(2):108-113.
   Google Scholar
• ANSARI MS, GUPTA NP: A comparison of lycopene and orchidectomy versus orchidectomy alone in the management of advanced prostate cancer. BJU Int. (2003) 92(4):375-378.
   PubMed Web of Science ®Google Scholar
• PORRINI M, RISO P, TESTOLIN G: Absorption of lycopene from single or daily portions of raw and processed tomato. Br. J. Nutr. (1998) 80(4):353-361.
   Web of Science ®Google Scholar
• FIELDING JM, ROWLEY KG, COOPER P, O’DEA K: Increases in plasma lycopene concentration after consumption of tomatoes cooked with olive oil. Asia Pac. J. Clin. Nutr. (2005) 14(2):131-136.
   Web of Science ®Google Scholar
• GIOVANNUCCI E: Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J. Nutr. (2005) 135(8):2030S-2031S.
   Google Scholar
• ETMINAN M, TAKKOUCHE B, CAAMANO-ISORNA F: The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol. Biomarkers Prev. (2004) 13(3):340-345.
   Web of Science ®Google Scholar
• KIM L, RAO AV, RAO LG: Effect of lycopene on prostate LNCaP cancer cells in culture. J. Med. Food (2002) 5(4):181-187.
   PubMedGoogle Scholar
• HWANG ES, BOWEN PE: Cell cycle arrest and induction of apoptosis by lycopene in LNCaP human prostate cancer cells. J. Med. Food (2004) 7(3):284-289.
   PubMed Web of Science ®Google Scholar
• KOTAKE-NARA E, KIM SJ, KOBORI M, MIYASHITA K, NAGAO A: Acyclo-retinoic acid induces apoptosis in human prostate cancer cells. Anti-Cancer Res. (2002) 22(2A):689-695.
   PubMed Web of Science ®Google Scholar
• TANG L, JIN T, ZENG X, WANG JS: Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. J. Nutr. (2005) 135(2):287-290.
   Google Scholar
• HWANG ES, BOWEN PE: Effects of lycopene and tomato paste extracts on DNA and lipid oxidation in LNCaP human prostate cancer cells. Biofactors (2005) 23(2):97-105.
   PubMed Web of Science ®Google Scholar
• CLINTON SK: The dietary antioxidant network and prostate carcinoma. Cancer (1999) 86(9):1629-1631.
   PubMed Web of Science ®Google Scholar
• MATOS HR, CAPELOZZI VL, GOMES OF, MASCIO PD, MEDEIROS MH: Lycopene inhibits DNA damage and liver necrosis in rats treated with ferric nitrilotriacetate. Arch. Biochem. Biophys. (2001) 396(2):171-177.
   Google Scholar
• CHEN L, STACEWICZ-SAPUNTZAKIS M, DUNCAN C et al.: Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J. Natl. Cancer Inst. (2001) 93(24):1872-1879.
   Google Scholar
• KUCUK O, SARKAR FH, SAKR W et al.: Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol. Biomarkers Prev. (2001) 10(8):861-868.
   Web of Science ®Google Scholar
• ANSARI MS, GUPTA NP: A comparison of lycopene and orchidectomy versus orchidectomy alone in the management of advanced prostate cancer. BJU Int. (2004) 94(4):678.
   PubMed Web of Science ®Google Scholar
• KIRSH VA, MAYNE ST, PETERS U et al.: A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. (2006) 15(1):92-98.
   Web of Science ®Google Scholar
• NOMURA AM, STEMMERMANN GN, LEE J, CRAFT NE: Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Cancer Epidemiol. Biomarkers Prev. (1997) 6(7):487-491.
   Web of Science ®Google Scholar
• GANN PH, MA J, GIOVANNUCCI E et al.: Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. (1999) 59(6):1225-1230.
   PubMed Web of Science ®Google Scholar
• GREENWALD P: Clinical trials in cancer prevention: current results and perspectives for the future. J. Nutr. (2004) 134(Suppl. 12):3507S-3512S.
   Google Scholar
• YU L, BLACKBURN GL, ZHOU JR: Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J. Nutr. (2003) 133(2):389-392.
   Google Scholar
• LEE MM, GOMEZ SL, CHANG JS, WEY M, WANG RT, HSING AW: Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol. Biomarkers Prev. (2003) 12(7):665-668.
   Web of Science ®Google Scholar
• KOLONEL LN, HANKIN JH, WHITTEMORE AS et al.: Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol. Biomarkers Prev. (2000) 9(8):795-804.
   Web of Science ®Google Scholar
• HEBERT JR, HURLEY TG, OLENDZKI BC, TEAS J, MA Y, HAMPL JS: Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J. Natl. Cancer Inst. (1998) 90:1637-1647.
   Google Scholar
• ADLERCREUTZ H: Epidemiology of phytoestrogens. Baillieres Clin. Endocrinol. Metab. (1998) 12:605-623.
   Web of Science ®Google Scholar
• JACOBSEN BK, KNUTSEN SF, FRASER GE: Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control (1998) 9(6):553-557.
   PubMed Web of Science ®Google Scholar
• AKIYAMA T, ISHIDA J, NAKAGAWA S et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. (1987) 262:5592-5595.
   PubMed Web of Science ®Google Scholar
• KUMI-DIAKA J, BUTLER A: Caspase-3 protease activation during the process of genistein-induced apoptosis in TM4 testicular cells. Biol. Cell (2000) 92:115-124.
   PubMed Web of Science ®Google Scholar
• CONSTANTINOU A, MEHTA R, RUNYAN C, RAO K, VAUGHAN A, MOON R: Flavonoids as DNA topoisomerase antagonists and poisons: structure–activity relationships. J. Nat. Prod. (1995) 58:217-225.
   PubMed Web of Science ®Google Scholar
• FOTIS T, PEPPER M, ADLERCREUTZ H et al.: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad. Sci. USA (1993) 90:2690-2694.
   Google Scholar
• LI M, ZHANG Z, HILL DL, CHEN X, WANG H, ZHANG R: Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res. (2005) 65(18):8200-8208.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI T, NAKATA T, KUZUMAKI T: Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett. (2002) 176(1):17-23.
   Web of Science ®Google Scholar
• SHEN JC, KLEIN RD, WEI Q et al.: Low-dose genistein induces cyclin-dependent kinase inhibitors and G1 cell-cycle arrest in human prostate cancer cells. Mol. Carcinog. (2000) 29:92-102.
   Google Scholar
• DAVIS JN, SINGH B, BHUIYAN M, SARKAR FH: Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr. Cancer (1998) 32:123-131.
   Web of Science ®Google Scholar
• BEMIS DL, CAPODICE JL, DESAI M, BUTTYAN R, KATZ AE: A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin. Cancer Res. (2004) 10(15):5282-5292.
   Google Scholar
• DALAIS FS, MELIALA A, WATTANAPENPAIBOON N et al.: Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology (2004) 64(3):510-515.
   PubMed Web of Science ®Google Scholar
• KUMAR NB, CANTOR A, ALLEN K et al.: The specific role of isoflavones in reducing prostate cancer risk. Prostate (2004) 59(2):141-147.
   PubMed Web of Science ®Google Scholar
• DE VERE WHITE RW, HACKMAN RM, SOARES SE, BECKETT LA, LI Y, SUN B: Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology (2004) 63(2):259-263.
   PubMed Web of Science ®Google Scholar
• CLARK LC, COMBS GF Jr, TURNBULL BW et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA (1996) 276:1957-1963.
   PubMed Web of Science ®Google Scholar
• a-TOCOPHEROL, β-CAROTENE CANCER PREVENTION STUDY GROUP: The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. (1994) 330(15):1029-1035.
   PubMed Web of Science ®Google Scholar
• DUFFIELD-LILLICO AJ, DALKIN BL, REID ME et al.: Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. (2003) 91(7):608-612.
   PubMed Web of Science ®Google Scholar
• HEINONEN OP, ALBANES D, VIRTAMO J et al.: Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J. Natl. Cancer Inst. (1998) 90(6):440-446.
   Google Scholar
• ETMINAN M, FITZGERALD JM, GLEAVE M, CHAMBERS K: Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control (2005) 16(9):1125-1131.
   PubMed Web of Science ®Google Scholar
• GOODMAN GE, SCHAFFER S, OMENN GS, CHEN C, KING I: The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from β-carotene and retinol efficacy trial. Cancer Epidemiol. Biomarkers Prev. (2003) 12(6):518-526.
   Web of Science ®Google Scholar
• EL-BAYOUMY K, RICHIE JP Jr, BOYIRI T et al.: Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. Cancer Epidemiol. Biomarkers Prev. (2002) 11(11):1459-1465.
   Web of Science ®Google Scholar
• MENTER DG, SABICHI AL, LIPPMAN SM: Selenium effects on prostate cell growth. Cancer Epidemiol. Biomarkers Prev. (2000) 9(11):1171-1182.
   Web of Science ®Google Scholar
• DONG Y, ZHANG H, HAWTHORN L, GANTHER HE, IP C: Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res. (2003) 63(1):52-59.
   PubMed Web of Science ®Google Scholar
• VENKATESWARAN V, FLESHNER NE, KLOTZ LH: Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J. Urol. (2002) 168(4 Part 1):1578-1582.
   Google Scholar
• EL-BAYOUMY K, SINHA R: Molecular chemoprevention by selenium: a genomic approach. Mutat. Res. (2005) 591(1-2):224-236.
   Google Scholar
• CHO SD, JIANG C, MALEWICZ B et al.: Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol. Cancer Ther. (2004) 3(5):605-611.
   Web of Science ®Google Scholar
• AZZI A, GYSIN R, KEMPNA P et al.: The role of α-tocopherol in preventing disease: from epidemiology to molecular events. Mol. Aspects Med. (2003) 24(6):325-336.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, NI J, MESSING EM, CHANG E, YANG CR, YEH S: Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc. Natl. Acad. Sci. USA (2002) 99(11):7408-7413.
   Google Scholar
• HANCHETTE CL, SCHWARTZ GG: Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer (1992) 70(12):2861-2869.
   PubMed Web of Science ®Google Scholar
• CORDER EH, GUESS HA, HULKA BS et al.: Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomarkers Prev. (1993) 2(5):467-472.
   Web of Science ®Google Scholar
• AHONEN MH, TENKANEN L, TEPPO L, HAKAMA M, TUOHIMAA P: Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control (2000) 11(9):847-852.
   PubMed Web of Science ®Google Scholar
• SKOWRONSKI RJ, PEEHL DM, FELDMAN D: Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology (1993) 132(5):1952-1960.
   PubMed Web of Science ®Google Scholar
• BLUTT SE, McDONNELL TJ, POLEK TC, WEIGEL NL: Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology (2000) 141(1):10-17.
   PubMed Web of Science ®Google Scholar
• TOKAR EJ, WEBBER MM: Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin. Exp. Metastasis (2005) 22(3):275-284.
   Google Scholar
• FELDMAN D, SKOWRONSKI RJ, PEEHL DM: Vitamin D and prostate cancer. Adv. Exp. Med. Biol. (1995) 375:53-63.
   PubMedGoogle Scholar
• KRISHNAN AV, PEEHL DM, FELDMAN D: Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J. Cell Biochem. (2003) 88(2):363-371.
   Google Scholar
• BOYLE BJ, ZHAO XY, COHEN P, FELDMAN D: Insulin-like growth factor binding protein-3 mediates 1 α,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J. Urol. (2001) 165(4):1319-1324.
   Google Scholar
• MORENO J, KRISHNAN AV, SWAMI S, NONN L, PEEHL DM, FELDMAN D: Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. (2005) 65(17):7917-7925.
   PubMed Web of Science ®Google Scholar
• GETZENBERG RH, LIGHT BW, LAPCO PE et al.: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology (1997) 50(6):999-1006.
   PubMed Web of Science ®Google Scholar
• TRUMP DL, HERSHBERGER PA, BERNARDI RJ et al.: Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol. (2004) 89-90(1-5):519-526.
   Web of Science ®Google Scholar
• OSBORN JL, SCHWARTZ GG, SMITH DC et al.: Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol. Oncol. (1995) 1:195-198.
   Google Scholar
• BEER TM, GARZOTTO M, HENNER WD, EILERS KM, WERSINGER EM: Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br. J. Cancer (2003) 89(6):968-970.
   PubMed Web of Science ®Google Scholar
• BEER TM: Development of weekly high-dose calcitriol based therapy for prostate cancer. Urol. Oncol. (2003) 21(5):399-405.
   Google Scholar
• SCHWARTZ GG, HALL MC, STINDT D, PATTON S, LOVATO J, TORTI FM: Phase I/II study of 19-nor-1α-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin. Cancer Res. (2005) 11(24 Part 1):8680-8685.
   Google Scholar
• LIU G, WILDING G, STAAB MJ, HORVATH D, MILLER K, DRESEN A: Phase II study of 1α-hydroxyvitamin D2 in the treatment of advanced androgen-independent prostate cancer. Clin. Cancer Res. (2003) 9(11):4077-4083.
   Google Scholar
• GIL MI, TOMAS-BARBERAN FA, HESS-PIERCE B, HOLCROFT DM, KADER AA: Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J. Agric. Food Chem. (2000) 48(10):4581-4589.
   PubMed Web of Science ®Google Scholar
• MALIK A, AFAQ F, SARFARAZ S, ADHAMI VM, SYED DN, MUKHTAR H: Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA (2005) 102(41):14813-14818.
   Google Scholar
• PANTUCK AJ, LEPPERT JT, ARONSON W et al.: Phase II study of pomegranate juice for men with rising prostate-specific antigenantigen following surgery or radiation for prostate cancer. Clin. Cancer Res. (2006) 12(13):4018-4026.
   PubMed Web of Science ®Google Scholar
• NELSON WG, DE MARZO AM, DEWEESE TL, ISAACS WB: The role of inflammation in the pathogenesis of prostate cancer. J. Urol. (2004) 172(5 Part 2):S6-S11.
   Google Scholar
• LUCIA MS, TORKKO KC: Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J. Urol. (2004) 171(2 Part 2):S30-S34.
   Google Scholar
• DE MARZO AM, MEEKER AK, ZHA S, LUO J, NAKAYAMA M, PLATZ EA: Human prostate cancer precursors and pathobiology. Urology (2003) 62(5 Suppl. 1):55-62.
   PubMedGoogle Scholar
• WAHLE KW, CARUSO D, OCHOA JJ, QUILES JL: Olive oil and modulation of cell signaling in disease prevention. Lipids (2004) 39(12):1223-1231.
   PubMed Web of Science ®Google Scholar
• KARMALI RA, MARSH J, FUCHS C: Effect of omega-3 fatty acids on growth of a rat mammary tumor. J. Natl. Cancer Inst. (1984) 73(2):457-461.
   Google Scholar
• VISIOLI F, BELLOMO G, MONTEDORO G, GALLI C: Low density lipoprotein oxidation is inhibited in vitro by olive oil constituents. Atherosclerosis (1995) 117(1):25-32.
   PubMed Web of Science ®Google Scholar
• QUILES JL, FARQUHARSON AJ, SIMPSON DK, GRANT I, WAHLE KW: Olive oil phenolics: effects on DNA oxidation and redox enzyme mRNA in prostate cells. Br. J. Nutr. (2002) 88(3):225-234.
   Web of Science ®Google Scholar
• BEMIS DL, CAPODICE JL, ANASTASIADIS AG, KATZ AE, BUTTYAN R: Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr. Cancer. (2005) 52(2):202-212.
   Web of Science ®Google Scholar